TradingView’s own chart and price feed. The page’s numbers are end-of-day closes.
Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.
The numbers
fiscal 2025, as filed with the SEC · 66-metric EOD snapshot via Databento
Market cap$18.2B
EV / True FCF27.4x
Revenue$2.5B +20.0%
True FCF (ex-SBC)$647.1M +19.2%
Rule of 4046.9%
Operating margin21.1%
True FCF Yield3.5%
EPS, diluted$15.28 +21.0%
Modern Valuation (EOD)
Market Cap$18.2B
Enterprise Value$17.7B
EV / True FCF27.40
EV / FCF26.00
EV / Gross Profit—
EV / EBIT33.15
EV / Sales7.01
P / E (GAAP)40.41
P / FCF26.73
P / Oper. CF25.56
P / Book39.71
Owner & Cash Yields
True FCF Yield3.5%
FCF Yield3.7%
Owner Earn. Yield2.3%
Earnings Yield2.5%
Shareholder Yield+4.8%
Buyback Yield5.0%
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh$24.38
EPS (diluted)$15.28
Compounder & Returns
Rule of 4046.9%
ROIC—
Cash ROIC (CROIC)—
GP / Assets—
ROE98.3%
ROA22.8%
Gross Margin—
Oper. Margin21.1%
Net Margin17.8%
FCF Margin26.9%
True FCF Margin25.6%
Quality & Dilution
Cash Conversion151%
Accrual Ratio−13.3%
SBC % of FCF5.1%
SBC % of Rev1.4%
Reinvest. Rate4%
Sales Growth Y/Y+20.0%
Sales 3Y CAGR+20.1%
EPS Growth Y/Y+21.0%
FCF Growth Y/Y+19.2%
FCF 3Y CAGR+24.8%
Share Change Y/Y−7.8%
Balance Sheet & Scale
Revenue (FY)$2.5B
Gross Profit (FY)—
Oper. Income (FY)$534.9M
GAAP Net Income$451.1M
True FCF (ex-SBC)$647.1M
Cash & Equiv$497.0M
Total Debt—
Net Cash (Debt)$497.0M
Net Cash % MCap+2.7%
Debt / FCF (yrs)0.0y
Current Ratio0.7427.97M sh
Price & Technicals (EOD)
Perf Week−3.48%
Perf Month−4.30%
Perf Quarter+2.13%
Perf Half Y+47.40%
Perf YTD+52.03%
SMA 20 Dist−3.90%$659.68
SMA 50 Dist−0.02%$634.13
SMA 100 Dist+4.65%$605.78
Window High−8.47%$692.68
Window Low+52.67%$415.27
RSI (14) · Vol44.832%v
Income Distribution & Cash Flow ConversionHow every dollar of MEDP revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
Standard Free Cash Flow (FCF)$681.9M(26.9% margin)
Less: Stock-Based Comp (SBC)−$34.8M(5.1% of FCF)
True FCF (Owner Cash ex-SBC)$647.1M(25.6% of rev)
Revenue by fiscal year
$1.1BFY21
$1.5BFY22
$1.9BFY23
$2.1BFY24
$2.5BFY25
Operating leverage — margins
GrossOperatingNet
Unlocked SEC EDGAR Accounting Statements (USD)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (USD)
FY2021
FY2022
FY2023
FY2024
FY2025
YoY Δ
4Y CAGR
Trend
Income Statement
Revenue ▸
$1.1B
$1.5B
$1.9B
$2.1B
$2.5B
+20.0%
+22.0%
Selling, General & Admin (SG&A)
$108.4M
$131.4M
$161.4M
$180.2M
$197.6M
+9.6%
+16.2%
Operating Income (EBIT) ▸
$198.6M
$278.7M
$336.8M
$446.9M
$534.9M
+19.7%
+28.1%
Income Tax Expense
$20.0M
$37.5M
$52.9M
$71.5M
$91.3M
+27.6%
+46.1%
GAAP Net Income ▸
$181.8M
$245.4M
$282.8M
$404.4M
$451.1M
+11.6%
+25.5%
Diluted EPS ▸
$4.81
$7.28
$8.88
$12.63
$15.28
+21.0%
+33.5%
Diluted Shares
37.7M
33.7M
31.8M
32.0M
29.5M
−7.8%
−5.9%
Balance Sheet
Cash & Equivalents
$461.3M
$28.3M
$245.4M
$669.4M
$497.0M
−25.8%
+1.9%
Total Current Assets
$690.9M
$334.0M
$593.8M
$1.0B
$989.6M
−3.8%
+9.4%
Total Assets
$1.7B
$1.4B
$1.7B
$2.1B
$2.0B
−6.0%
+4.4%
Total Current Liabilities
$557.2M
$803.5M
$925.1M
$1.1B
$1.3B
+21.7%
+24.6%
Total Debt (Short + Long Term)
$0
$0
$0
$0
$0
—
—
Total Liabilities
$707.0M
$966.1M
$1.1B
$1.3B
$1.5B
+18.9%
+21.0%
Stockholders' Equity
$952.9M
$386.4M
$559.0M
$825.5M
$459.1M
−44.4%
−16.7%
Net Cash / (Net Debt)
$461.3M
$28.3M
$245.4M
$669.4M
$497.0M
−25.8%
+1.9%
Invested Capital
$491.6M
$358.1M
$313.5M
$156.1M
$-38.0M
−124.3%
—
Cash Flow & Capital Allocation
Operating Cash Flow (OCF) ▸
$263.3M
$388.1M
$433.4M
$608.8M
$713.2M
+17.1%
+28.3%
Depreciation & Amortization (D&A)
$16.0M
$19.0M
$24.1M
$27.8M
$27.2M
−2.3%
+14.2%
Stock-Based Compensation (SBC)
$14.5M
$21.4M
$20.5M
$25.5M
$34.8M
+36.3%
+24.5%
Capital Expenditures (CapEx)
$28.3M
$36.9M
$36.6M
$36.5M
$31.4M
−14.2%
+2.6%
Free Cash Flow (FCF) ▸
$235.1M
$351.2M
$396.7M
$572.3M
$681.9M
+19.2%
+30.5%
True FCF (ex-SBC Owner Cash)
$220.6M
$329.8M
$376.2M
$546.8M
$647.1M
+18.3%
+30.9%
Share Repurchases (Buybacks)
$62.1M
$847.8M
$144.0M
$169.9M
$917.4M
+440.1%
+96.1%
Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.
On the Wire
what MEDP did at the next close after each story
No Wire story has named MEDP yet.
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.
What happened · big days
22 big days in a year, and what we hold on each
A big day is a close more than 3.49% from the one before, three times MEDP’s median day (1.16%). On 13 of the 22, its peer group moved the same way at least half as far. We show what we hold. We never name a cause.
every other trading daya big day, numbered in the list below±3.49%Hover a bar for its day. Click a big day to open it.
Shaded: since our stories began, Jun 10. Tap a bar for its day.
#DayMEDPWhat we hold that dayGroup (median of 4) · each
1 Nov 24, 2025+4.51%
Before our storiesgroup +1.6%, did not move with it
1Nov 24, 2025+4.51%
Before our stories
+1.6% did not move with itINCY +4.1 · CRL +1.7 · IQV +1.5 · ICLR −0.0
2 Dec 4, 2025−5.50%
Before our storiesgroup −1.0%, did not move with it
2Dec 4, 2025−5.50%
Before our stories
−1.0% did not move with itICLR −1.1 · IQV −1.0 · INCY −1.0 · CRL −0.3
3 Jan 6, 2026+3.76%
Before our storiesgroup +3.1%, moved with MEDP
3Jan 6, 2026+3.76%
Before our stories
+3.1% moved with MEDPINCY +4.8 · CRL +3.7 · IQV +2.5 · ICLR +2.0
4 Feb 5, 2026−3.61%
Before our storiesgroup −9.8%, moved with MEDP
4Feb 5, 2026−3.61%
Before our stories
−9.8% moved with MEDPICLR −10.9 · IQV −10.7 · CRL −8.9 · INCY +0.2
5 Feb 10, 2026−15.90%
Resultsgroup −5.9%, did not move with it
5Feb 10, 2026−15.90%
ResultsFirst close after the Feb 9 results filing
−5.9% did not move with itINCY −8.2 · ICLR −6.5 · IQV −5.3 · CRL −2.4
6 Feb 11, 2026−4.96%
Before our storiesgroup −5.4%, moved with MEDP
6Feb 11, 2026−4.96%
Before our stories
−5.4% moved with MEDPCRL −8.4 · ICLR −7.9 · IQV −2.9 · INCY −1.2
7 Feb 18, 2026+4.20%
Before our storiesgroup +2.9%, moved with MEDP
7Feb 18, 2026+4.20%
Before our stories
+2.9% moved with MEDPICLR +8.9 · IQV +4.0 · INCY +1.8 · CRL −0.3
8 Mar 12, 2026−7.09%
Before our storiesgroup −6.3%, moved with MEDP
8Mar 12, 2026−7.09%
Before our stories
−6.3% moved with MEDPCRL −9.6 · ICLR −7.5 · IQV −5.0 · INCY −2.8
9 Mar 31, 2026+4.32%
Before our storiesgroup +4.8%, moved with MEDP
9Mar 31, 2026+4.32%
Before our stories
+4.8% moved with MEDPCRL +8.0 · ICLR +5.3 · INCY +4.2 · IQV +2.6
10 Apr 9, 2026−3.68%
Before our storiesgroup +0.2%, did not move with it
10Apr 9, 2026−3.68%
Before our stories
+0.2% did not move with itIQV −2.1 · ICLR +0.1 · CRL +0.3 · INCY +1.1
11 Apr 14, 2026+3.74%
Before our storiesgroup +2.1%, moved with MEDP
11Apr 14, 2026+3.74%
Before our stories
+2.1% moved with MEDPICLR +2.4 · INCY +2.2 · IQV +1.9 · CRL +0.5
12 Apr 23, 2026−22.63%
Resultsgroup −8.1%, did not move with it
12Apr 23, 2026−22.63%
ResultsFirst close after the Apr 22 results filing
−8.1% did not move with itCRL −9.2 · IQV −8.3 · ICLR −7.9 · INCY −1.3
13 Apr 24, 2026+4.35%
Before our storiesgroup +0.1%, did not move with it
13Apr 24, 2026+4.35%
Before our stories
+0.1% did not move with itCRL +1.2 · IQV +1.0 · INCY −0.9 · ICLR −3.9
14 May 28, 2026+4.70%
Before our storiesgroup +9.8%, moved with MEDP
14May 28, 2026+4.70%
Before our stories
+9.8% moved with MEDPICLR +15.5 · CRL +10.2 · IQV +9.3 · INCY +0.2
15 Jun 23, 2026+3.91%
Nothing on MEDPgroup +1.7%, did not move with it
15Jun 23, 2026+3.91%
Nothing on MEDPNo MEDP story, brief or results filing in our record that day
+1.7% did not move with itCRL +2.8 · IQV +2.1 · ICLR +1.4 · INCY +0.7
16 Jun 24, 2026+8.30%
Nothing on MEDPgroup +8.3%, moved with MEDP
16Jun 24, 2026+8.30%
Nothing on MEDPNo MEDP story, brief or results filing in our record that day
+8.3% moved with MEDPICLR +10.9 · IQV +8.4 · CRL +8.3 · INCY +3.9
17 Jul 23, 2026+14.71%
Resultsgroup +3.1%, did not move with it
17Jul 23, 2026+14.71%
ResultsFirst close after the Jul 22 results filing
+3.1% did not move with itCRL +4.8 · IQV +4.4 · ICLR +1.8 · INCY +0.8
18 Sep 15, 2026+4.21%
Nothing on MEDPgroup +0.7%, did not move with it
18Sep 15, 2026+4.21%
Nothing on MEDPNo MEDP story, brief or results filing in our record that day
+0.7% did not move with itICLR +2.1 · IQV +1.5 · CRL −0.1 · INCY −0.4
19 Oct 1, 2026−4.18%
Nothing on MEDPgroup −3.3%, moved with MEDP
19Oct 1, 2026−4.18%
Nothing on MEDPNo MEDP story, brief or results filing in our record that day
−3.3% moved with MEDPICLR −4.8 · INCY −3.5 · IQV −3.0 · CRL −2.8
20 Oct 5, 2026+3.51%
Nothing on MEDPgroup +3.5%, moved with MEDP
20Oct 5, 2026+3.51%
Nothing on MEDPNo MEDP story, brief or results filing in our record that day
+3.5% moved with MEDPCRL +7.1 · ICLR +3.9 · IQV +3.0 · INCY −1.0
21 Oct 21, 2026+6.43%
Nothing on MEDPgroup +4.8%, moved with MEDP
21Oct 21, 2026+6.43%
Nothing on MEDPNo MEDP story, brief or results filing in our record that day
+4.8% moved with MEDPCRL +9.3 · ICLR +6.3 · IQV +3.3 · INCY −2.7
22 Oct 30, 2026−3.77%
Nothing on MEDPgroup −2.4%, moved with MEDP
22Oct 30, 2026−3.77%
Nothing on MEDPNo MEDP story, brief or results filing in our record that day
−2.4% moved with MEDPCRL −4.4 · IQV −2.8 · ICLR −1.9 · INCY +3.1
A story on the same day is not a cause, and a group move is not proof either. Group: the median of IQV, INCY, CRL and ICLR that day, the largest companies in MEDP’s SEC industry; “moved with MEDP” means the same direction and at least half the size.
What’s next · results
Before the next report: what the first day after the last four did
Six trading days after each results filing (SEC 8-K, Item 2.02). MEDP reports after the close, so day 1 is the next close. 3 of 4 times, day 6 ended on the same side as day 1.
Reported Feb 9, 2026
day 1−15.90%day 6−15.87%
Reported Apr 22, 2026
day 1−22.63%day 6−17.66%
Reported Jul 22, 2026
day 1+14.71%day 6+9.50%
Reported Oct 21, 2026
day 1−1.29%day 6+2.28%
Next report: expected mid January to early FebruaryEstimated from the dates of its last four results filings. Not announced. Since the Oct 21 report: −2.36%. Four reports is a small sample.
Each line is MEDP’s close against its close before the filing, on licensed end-of-day closes. What happened after each report, not a forecast; a move on the day is not a cause.
Same industry
MEDP against four same-industry peers, a year at 100
MEDP is up 9.3% in a year. Charles River Laboratories International is up 98.8%, Icon 18.6%, Incyte 15.4% and IQVIA Holdings 14.7%. All four did more. Weekly closes, Nov 21, 2025 = 100, on a log scale, so the same percentage move is the same height on every line.
End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in MEDP’s SEC industry (Services-Commercial Physical & Biological Research) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.